Successful Weight Loss With Mounjaro (Tirzepatide)
Obesity is a chronic metabolic disease that increases the risk of conditions such as type 2 diabetes, hypertension, dyslipidaemia, and cardiovascular disease. For individuals with class II obesity and multiple cardiometabolic risk factors, a structured treatment approach combining lifestyle modification with appropriate medical therapy can lead to meaningful and sustained weight loss.
This case highlights the one-year clinical outcome of a patient treated with Mounjaro (tirzepatide), alongside dietary changes, physical activity and ongoing follow-up.
Patient Information
- Age/Sex: 38-year-old male
- Occupation: Business professional
- Height: 170 cm
- Baseline Weight: 108 kg
- Baseline BMI: 37.4 kg/m²
- Waist Circumference: 116 cm
Risk Status
The patient was considered to have high cardiometabolic risk due to:
- Class II obesity
- Central adiposity
- Sedentary lifestyle
- Family history of Type 2 Diabetes
Presenting Complaints
The patient presented with:
- Progressive weight gain over 8 years
- Increased abdominal fat
- Reduced exercise tolerance
- Snoring and daytime tiredness
- Difficulty achieving sustained weight loss despite multiple diet attempts
He had previously attempted calorie restriction and regular walking, but the weight loss was not sustained.
Relevant Medical History
The patient had:
- No known diabetes
- Mild hypertension
- Dyslipidaemia
- Sedentary lifestyle
- Family history of Type 2 Diabetes
- No previous bariatric surgery
Diagnostic Assessment
Baseline Investigations
Investigation | Baseline |
Fasting glucose | 108 mg/dL |
HbA1c | 5.80% |
Triglycerides | 196 mg/dL |
LDL-C | 132 mg/dL |
ALT | 58 U/L |
Blood pressure | 142/88 mmHg |
The baseline findings were consistent with obesity-associated cardiometabolic risk, without established diabetes.
Therapeutic Intervention
After assessment for contraindications and discussion of available obesity treatment options, tirzepatide (Mounjaro) was initiated alongside a structured lifestyle programme.
Medication
Treatment included:
- Tirzepatide 2.5 mg subcutaneously once weekly initially
- Gradual dose escalation according to response and tolerability
- Combination with a calorie-controlled, high-protein diet and progressive physical activity
Dose escalation should be individualised and follow locally approved prescribing information.
Lifestyle Intervention
The patient’s lifestyle programme included:
- Individualised calorie deficit
- Protein-rich meals
- Increased vegetables and fibre
- Reduction in refined carbohydrates, sugary drinks and ultra-processed foods
- Walking initially for 30 minutes daily
- Progressive resistance training 2 to 3 times per week
- Sleep optimisation
Follow-Up
One-Year Results
After one year of treatment:
- Total weight loss: 21.5 kg
- Percentage weight loss: 19.9%
- Waist circumference: Reduced from 116 cm to 96 cm
Metabolic Response
Several cardiometabolic parameters improved over 12 months.
Parameter | Baseline | 12 Months |
HbA1c | 5.80% | 5.40% |
Fasting glucose | 108 mg/dL | 94 mg/dL |
Triglycerides | 196 mg/dL | 138 mg/dL |
Blood pressure | 142/88 mmHg | Approximately 126/80 mmHg |
ALT | 58 U/L | 34 U/L |
The patient also reported improved exercise tolerance and reduced snoring.
Adverse Effects
During the initial dose-escalation period, the patient experienced:
- Mild nausea
- Early satiety
- Occasional constipation
These symptoms were transient and managed with smaller meals, adequate hydration, dietary modification and slower dose escalation when required.
No serious adverse events occurred.
Clinical Outcome
After one year of treatment, the patient achieved approximately 20% total body-weight reduction, with substantial reduction in waist circumference and improvement in several cardiometabolic parameters.
The patient continued lifestyle modification and was counselled that obesity is a chronic disease requiring long-term treatment and follow-up to help maintain weight loss.
Key Learning Points
- Obesity should be approached as a chronic metabolic disease rather than simply a lifestyle issue.
- Tirzepatide can produce substantial weight reduction when combined with lifestyle intervention.
- Treatment should include dietary modification, physical activity and behavioural support.
- Gradual dose escalation can improve gastrointestinal tolerability.
- Weight, waist circumference, metabolic parameters and adverse effects should be monitored regularly.
- Long-term weight maintenance planning is important because weight regain can occur after discontinuation of effective anti-obesity therapy.
Discussion
This case demonstrates how combining tirzepatide with structured lifestyle modification can achieve clinically meaningful weight loss and improve several cardiometabolic risk factors over one year. Regular monitoring of weight, waist circumference, blood pressure and metabolic markers helped assess progress throughout treatment.
Gradual dose escalation also played an important role in improving treatment tolerability, while continued lifestyle changes supported long-term weight management.
Conclusion
This case highlights the value of a comprehensive approach to obesity management that combines appropriate medical therapy with sustainable lifestyle changes. Significant improvements in body weight, waist circumference and metabolic health can be achieved with consistent treatment and follow-up.
For professional medical guidance, weight management assessment or personalised obesity care, please contact us to connect with the healthcare team.
Note: This case study is for illustrative and educational purposes only and should not replace professional medical advice. If you have concerns about your weight or overall health, please consult a qualified healthcare provider.
